Galderma has provided a progress update on its Biologics License Application (BLA) for relabotulinum toxin A, its proprietary neuromodulator candidate, currently under FDA review. While the company did not disclose a specific approval timeline, the filing remains active, positioning relabotulinum as a potential third major botulinum toxin option alongside Botox and Jeuveau in the U.S. market.
Regulatory
Galderma Updates Relabotulinum BLA Status With FDA — Third Neuromodulator Nears U.S. Approval
Regulatory progress on Galderma's botulinum toxin candidate; competitive pressure on pricing.
Relabotulinum moves through FDA review as a potential third neuromodulator option.
Relabotulinum differs from existing toxins in its manufacturing process and formulation, with clinical data suggesting a rapid onset and potentially longer duration. If approved, it would fragment the neuromodulator market further, intensifying price competition and forcing practices to evaluate unit economics across three platforms. Galderma's existing injectable portfolio (Restylane fillers, Dysport) gives it distribution leverage, but market share gains will hinge on rebate programs, clinical differentiation, and whether practices see meaningful clinical or economic advantage over entrenched competitors.
Source: original report ↗
Frequently asked questions
What is relabotulinum and how is it different from Botox and Jeuveau?
Relabotulinum is Galderma's proprietary botulinum toxin candidate currently under FDA review. It differs from Botox and Jeuveau in its manufacturing process and formulation, with clinical data suggesting faster onset and potentially longer duration of results, offering a third major neuromodulator option if approved.
When will relabotulinum be approved by the FDA?
Galderma has not disclosed a specific approval timeline, though the Biologics License Application (BLA) remains active under FDA review. The company has only confirmed the filing is progressing, so practices should monitor regulatory announcements for official approval status.
How will relabotulinum approval affect botox pricing and market competition?
A third major neuromodulator option will intensify price competition in the market, forcing practices to evaluate unit economics across three platforms. Galderma's existing distribution leverage with Restylane and Dysport may help, but market share gains will depend heavily on rebate programs and whether practices see meaningful clinical or economic advantages.
What advantages does Galderma have in launching relabotulinum?
Galderma already distributes Restylane fillers and Dysport, giving it established relationships and distribution leverage with practices. This existing portfolio positions the company to bundle relabotulinum into rebate programs and cross-sell strategies, though clinical differentiation and pricing will ultimately drive adoption.
Will relabotulinum replace Botox or Jeuveau in practices?
Relabotulinum will likely coexist with Botox and Jeuveau rather than replace them, fragmenting the market further. Practices will choose based on clinical results, pricing, rebates, and patient outcomes, so most will likely maintain relationships with multiple neuromodulator platforms.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.